Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM, Poole CJ; tAnGo Trial Collaborators. Wardley AM, et al. Among authors: poole cj. Br J Cancer. 2008 Aug 19;99(4):597-603. doi: 10.1038/sj.bjc.6604538. Epub 2008 Jul 29. Br J Cancer. 2008. PMID: 18665163 Free PMC article. Clinical Trial.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators. Earl HM, et al. Among authors: poole cj. Lancet Oncol. 2017 Jun;18(6):755-769. doi: 10.1016/S1470-2045(17)30319-4. Epub 2017 May 4. Lancet Oncol. 2017. PMID: 28479233 Free article. Clinical Trial.
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life.
Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O'Reilly S, Rea DW, Spooner D, Poole CJ; NEAT Investigators. Earl HM, et al. Among authors: poole cj. Br J Cancer. 2008 Oct 21;99(8):1226-31. doi: 10.1038/sj.bjc.6604674. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797468 Free PMC article. Clinical Trial.
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.
Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RC, Twelves CJ, Cameron D, Bartlett JM, Pharoah P, Provenzano E, Caldas C, Poole CJ; NEAT Investigators and the SCTBG. Earl HM, et al. Among authors: poole cj. Br J Cancer. 2012 Oct 9;107(8):1257-67. doi: 10.1038/bjc.2012.370. Epub 2012 Sep 11. Br J Cancer. 2012. PMID: 23047592 Free PMC article. Clinical Trial.
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators. Hall E, et al. Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007. Epub 2014 Jul 24. Eur J Cancer. 2014. PMID: 25065293 Free PMC article. Clinical Trial.
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.
Ali AM, Provenzano E, Bartlett JM, Abraham J, Driver K, Munro AF, Twelves C, Poole CJ, Hiller L, Dunn JA, Earl HM, Caldas C, Pharoah PD. Ali AM, et al. Among authors: poole cj. Int J Cancer. 2013 Sep 15;133(6):1470-8. doi: 10.1002/ijc.28150. Epub 2013 Apr 18. Int J Cancer. 2013. PMID: 23483540 Free article.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Abraham JE, Hiller L, Dorling L, Vallier AL, Dunn J, Bowden S, Ingle S, Jones L, Hardy R, Twelves C, Poole CJ, Pharoah PD, Caldas C, Earl HM. Abraham JE, et al. Among authors: poole cj. BMC Med. 2015 Dec 29;13:306. doi: 10.1186/s12916-015-0547-5. BMC Med. 2015. PMID: 26715442 Free PMC article.
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG. Poole CJ, et al. N Engl J Med. 2006 Nov 2;355(18):1851-62. doi: 10.1056/NEJMoa052084. N Engl J Med. 2006. PMID: 17079759 Free article. Clinical Trial.
135 results